Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Up 8.1% in June

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) was the recipient of a significant growth in short interest in June. As of June 15th, there was short interest totalling 3,880,000 shares, a growth of 8.1% from the May 31st total of 3,590,000 shares. Based on an average daily trading volume, of 570,600 shares, the short-interest ratio is presently 6.8 days.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on FULC. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Fulcrum Therapeutics in a report on Tuesday, May 14th. The Goldman Sachs Group upgraded Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $6.00 to $15.00 in a research report on Monday, May 13th. Royal Bank of Canada assumed coverage on Fulcrum Therapeutics in a research report on Wednesday, March 13th. They issued an “outperform” rating and a $14.00 price target on the stock. Cantor Fitzgerald assumed coverage on Fulcrum Therapeutics in a research note on Monday, May 20th. They set an “overweight” rating and a $23.00 price objective for the company. Finally, Oppenheimer decreased their price objective on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 14th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $15.57.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in FULC. FMR LLC increased its holdings in Fulcrum Therapeutics by 7.6% during the 3rd quarter. FMR LLC now owns 5,975,416 shares of the company’s stock worth $26,531,000 after purchasing an additional 421,676 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Fulcrum Therapeutics by 0.7% during the first quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company’s stock worth $23,965,000 after buying an additional 18,681 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Fulcrum Therapeutics by 4.3% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,406,422 shares of the company’s stock worth $10,685,000 after acquiring an additional 100,000 shares during the last quarter. Vestal Point Capital LP bought a new position in shares of Fulcrum Therapeutics during the 4th quarter worth approximately $6,919,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $4,302,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

Shares of Fulcrum Therapeutics stock opened at $6.16 on Thursday. Fulcrum Therapeutics has a 52 week low of $3.14 and a 52 week high of $13.70. The stock has a market capitalization of $382.53 million, a price-to-earnings ratio of -3.85 and a beta of 2.29. The firm has a fifty day moving average of $7.35 and a two-hundred day moving average of $8.05.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.01. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 40.60%. As a group, research analysts forecast that Fulcrum Therapeutics will post -1.24 EPS for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.